A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes

Authors:
  • RER. Evans
    R. Evans
  • STS. Tanaka
    S. Tanaka
  • STS. Touno
    S. Touno
  • KSK. Shimizu
    K. Shimizu
  • SSS. Sakui
    S. Sakui
  • JWJ. Wu
    J. Wu
  • HFH. Faessel
    H. Faessel
  • YHY. Hang
    Y. Hang
  • RAR. Alexander
    R. Alexander
  • LRL. Rosen
    L. Rosen
  • DHD. Hartman
    D. Hartman

Abstract
No abstract available